



**Board of Directors Report
For the Financial Period January/December 2024
(Consolidated Statements)**

We present the Board of Directors' report on the consolidated financial statements for the period from January 1, 2024, to December 31, 2024, for the Egyptian International Pharmaceutical Industries Company (EIPICO).

Company Overview:

Purpose: EIPICO engages in pharmaceuticals, medical products, cosmetics, chemicals, veterinary products, pesticides, dietary supplements, medical plants, special foods, glass ampoule manufacturing, and plastic pharmaceutical packaging. It operates within and beyond Egypt.

The duration of the company has been extended to twenty-five years, commencing from December 18, 2005, and ending on December 17, 2030, with the possibility of renewal for a similar period by a decision of the Extraordinary General Assembly.

The company is subject to Law No. 43 of 1974, as amended by Law No. 32 of 1977.

Key Data:

Authorized Capital: EGP 1,500,000,000

Paid-Up Capital: EGP 1,487,557,500

Issued Capital: EGP 1,487,557,500

Nominal Value per Share: EGP 10

Commercial Registry Number and Date: 11116, December 3, 1980



As we conclude the fiscal year 2024, we present the following significant achievements:

1. Net Sales (Revenue):

Category	During the Period (Million EGP)	Comparable Period (Million EGP)	Increase/Decrease (Million EGP)	Percentage (%)
Domestic Market Net Sales	4420.5	3,149.5	1,271	40%
Tender Sales Net Sales	634	475	159.05	33%
Export Net Sales	2,500.2	1,592	908	%57
Toll Sales to Others	35,8	15,1	20,7	137%
Total Company Net Sales	7,590.5	5,232	2,359	45%

2.

Cost of Goods Sold:

Category	During the Period (Million EGP)	Comparable Period (Million EGP)	Increase/Decrease (Million EGP)	Percentage (%)
Cost of Goods Sold	4,184	2,896	1,288	44.5%
Cost of Goods Sold to Net Sales	55.1%	%55.4	-	-

3. Production:

Category	During the Period (Million EGP)	Comparable Period (Million EGP)	Increase/Decrease (Million EGP)	Percentage (%)
Production Value	8,475	5,957	2,518	42.3%



4. Profitability:

Category	During the Period (Million EGP)	Comparable Period (Million EGP)	Increase/Decrease (Million EGP)	Percentage (%)
Gross Profit	3,406	2,335	1,071	46%
Net Profit Before Tax	1,530	1,083	447	41%
Net Profit After Tax	1,097	823	274	33%

5. Assets under construction:

Category	During the Period (Million EGP)	December 31, 2023 (Million EGP)	Increase/Decrease (Million EGP)	Percentage (%)
Assets under construction	5,694	3,058	2,636	86%

6. Cash Flows and Cash Balances:

Category	During the Period (Million EGP)	Comparable Period (Million EGP)	Increase/Decrease (Million EGP)	Percentage (%)
Cash Flows from Operations	(1,277)	90	(1,367)	(1,518%)
Cash Flows from Investing	(2,679)	(2,330)	349	15%
Cash Flows from Financing	3,856	2,210	1,646	75%
Net Cash Flow for the Period	(100)	(29.4)	(70.6)	239%
Exchange Rate Impact on Cash	719	222	497	224%
Cash Balance at the Beginning	676	483	193	40%
Cash Balance on December 31, 2024	1,295	676	620	92%



7. Capital:

Category	During the Period (Million EGP)	Comparable Period (Million EGP)	Increase/Decrease (Million EGP)	Percentage (%)
Capital	1,487.5	1,487.5	-	-

8. Treasury Shares:

Category	During the Period (Million EGP)	December 31, 2022 (Million EGP)	Increase/Decrease (Million EGP)	Percentage (%)
Treasury Shares	0	0	0	0

9. Equity (Including Surplus of the Period):

Category	During the Period (Million EGP)	December 31, 2023 (Million EGP)	Increase/Decrease (Million EGP)	Percentage (%)
Equity (Including Surplus)	4,658	4,261	397	9%

Accept our sincere regards and respect.

Chairman of the Board of Directors

Dr. Ahmed Kelani

